Truncal Ultrasound Guided Regional Anesthesia for Implantation and Revision of Automatic Implantable Cardioverter Defibrillators (AICDs) and Pacemakers in Pediatric Patients
Truncal Ultrasound Guided Regional Anesthesia for Implantation and Revision of AICDs and Pacemakers in Pediatric Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Olga Pewelek, MD
- Phone Number: 7135006227
- Email: Olga.I.Lyuksyutova@uth.tmc.edu
Study Contact Backup
- Name: Kelbie J Kerr
- Phone Number: 225-715-1371
- Email: Kelbie.J.Kerr@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing implantation or revision of pacemaker or AICD in the pediatric cath lab
Exclusion Criteria:
- parent or patient refusal
- use of narcotic medications prior to procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Local Anesthetic (LA Group)
|
In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
|
|
Active Comparator: B group
|
In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total Narcotic Dose in Milligram Morphine Equivalents (MME) Per Kilogram
Time Frame: From 24 hours after procedure to 48 hours after procedure
|
From 24 hours after procedure to 48 hours after procedure
|
|
Total Narcotic Dose in Milligram Morphine Equivalents (MME) Per Kilogram
Time Frame: up to 24 hours after procedure
|
up to 24 hours after procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain as Measured by the Visual Analog Scale (VAS) Pain Score
Time Frame: up to 1.5 hours post procedure in post anesthesia care unit (PACU)
|
VAS pain scale is a range of scores from 0-100.
A higher score indicates greater pain intensity.
|
up to 1.5 hours post procedure in post anesthesia care unit (PACU)
|
|
Pain as Measured by the Visual Analog Scale (VAS) Pain Score
Time Frame: up to 24 hours post procedure
|
VAS pain scale is a range of scores from 0-10.
A higher score indicates greater pain intensity.
|
up to 24 hours post procedure
|
|
Pain as Measured by the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Assessment Scale
Time Frame: up to 6 hours post procedure in post anesthesia care unit (PACU)
|
Face, Legs, Activity, Cry, Consolability (FLACC) Pain Assessment measures pain with a total score that ranges from 0 to 10; a higher score indicating greater pain.
|
up to 6 hours post procedure in post anesthesia care unit (PACU)
|
|
Number of Patients With the Incidence of Pruritis
Time Frame: up to 48 hours after procedure
|
up to 48 hours after procedure
|
|
|
Number of Patients With the Incidence of Nausea/Vomiting
Time Frame: up to 48 hours after procedure
|
up to 48 hours after procedure
|
|
|
Number of Patients With Respiratory Depression
Time Frame: up to 48 hours after procedure
|
up to 48 hours after procedure
|
|
|
Number of Patients With Local Anesthetic Toxicity
Time Frame: up to 48 hours after procedure
|
up to 48 hours after procedure
|
|
|
Number of Patients With Incidence of Pneumothorax
Time Frame: up to 48 hours after procedure
|
up to 48 hours after procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olga Pewelek, MD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-19-0760
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.